Strive Asset Management, LLC (ASST)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
The Manufacturing, Marketing, and Sales of Its Patented and FDA Cleared Product, Quantaflo	3.65M	2.45M
The Manufacturing, Marketing, and Sales of Its Patented and FDA Cleared Product, Quantaflo Growth	49.00%	-
Total	3.65M	2.45M
Total Growth	49.00%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
United States	3.65M	2.45M
United States Growth	49.00%	-
Total	3.65M	2.45M
Total Growth	49.00%	-

Source: S&P Global Market Intelligence.